@article {27050,
	title = {Overexpression of BCL2 and BAX following BFM induction therapy predicts ch-ALL patients{\textquoteright} poor response to treatment and short-term relapse},
	journal = {J Cancer Res Clin Oncol},
	volume = {141},
	number = {11},
	year = {2015},
	note = {Stamati, LampriniAvgeris, MargaritisKosmidis, HelenBaka, MargaritaAnastasiou, TheodoraPiatopoulou, DespinaScorilas, AndreasGourgiotis, DimitriosengGermany2015/05/20 06:00J Cancer Res Clin Oncol. 2015 Nov;141(11):2023-36. doi: 10.1007/s00432-015-1982-6. Epub 2015 May 16.},
	month = {Nov},
	pages = {2023-36},
	abstract = {PURPOSE: The identification of childhood acute lymphoblastic leukemia (ch-ALL) patients who are at a higher risk of chemotherapy resistance and relapse is essential for successful treatment decisions, despite the application of novel therapies. The aim of the study is the evaluation of BCL2 and BAX expression for the prognosis of ch-ALL patients treated with Berlin-Frankfurt-Munster (BFM) backbone protocol. METHODS: Bone marrow specimens were obtained at the time of diagnosis and on day 33 following BFM treatment induction from 82 ch-ALL patients, as well as from 63 healthy children. Following extraction, total RNA was reverse transcribed and BCL2 and BAX expression levels were determined by qPCR. RESULTS: BCL2 expression and BCL2/BAX ratio were strongly upregulated in ch-ALL compared to healthy children and were correlated with favorable prognostic disease features. Increased levels of BCL2 and BAX expression were associated with disease remission, as ch-ALL patients with lower expression ran a significantly higher risk of M2-M3 response, positive MRD and poor survival outcome. Moreover, the upregulation of BCL2 and BAX following BFM treatment induction was shown to represent an independent predictor of patients{\textquoteright} short-term relapse, which was further confirmed in ch-ALL patients with favorable prognostic markers. CONCLUSIONS: In conclusion, BCL2 and BAX could be effectively used for an enhanced prediction of BFM-treated patients{\textquoteright} outcome.},
	keywords = {Adolescent, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, apoptosis, Asparaginase/therapeutic use, bcl-2-Associated X Protein/biosynthesis/*metabolism, Berlin-Frankfurt-Munster treatment protocol, Biomarkers, Tumor/genetics, Bone Marrow Cells/metabolism, Bone Marrow/metabolism, Chemotherapy resistance, Child, Child, Preschool, Childhood acute lymphoblastic leukemia (ch-ALL), Daunorubicin/therapeutic use, Disease-Free Survival, Female, Humans, Induction Chemotherapy/methods, Infant, Male, molecular tumor markers, Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy/genetics/mortality, Prednisone/therapeutic use, Proto-Oncogene Proteins c-bcl-2/biosynthesis/*metabolism, Treatment Outcome, Up-Regulation, Vincristine/therapeutic use},
	isbn = {1432-1335 (Electronic)0171-5216 (Linking)},
	author = {Stamati, L. and Avgeris, M. and Kosmidis, H. and Baka, M. and Anastasiou, T. and Piatopoulou, D. and Scorilas, A. and Gourgiotis, D.}
}
